BMS wins first CELMoD drug approval for myeloma

Good morning, healthcare professional.

Today brings a landmark FDA approval for Bristol Myers Squibb, positive pivotal trial results for companies betting on novel mechanisms, and heightened regulatory scrutiny of the nation's largest health insurer. From first-in-class cancer treatments to drugs addressing post-bariatric surgery complications, innovation continues across therapeutic areas.

These developments signal both scientific progress and increased oversight in healthcare. The approval of new drug classes expands treatment options for patients, while regulatory investigations remind us that compliance remains paramount for industry leaders.

In today's healthcare digest:

• Bristol Myers Squibb secures FDA approval for Zenbexus, launching the CELMoD drug class in multiple myeloma
• Amylyx reports pivotal trial success for avexitide, a GLP-1 blocker treating post-bariatric hypoglycemia
• Argenx announces Phase 3 wins for Vyvgart in autoimmune indications, positioning for regulatory filing
• IRS opens investigation into UnitedHealth Group over potential tax avoidance practices

Bristol Myers Squibb Launches CELMoD Class with Zenbexus Approval

The FDA has approved Bristol Myers Squibb's Zenbexus for multiple myeloma, marking the first approval in the CELMoD (cereblon E3 ligase modulator) drug class. This milestone validates a key franchise BMS acquired through its $74 billion Celgene purchase in 2019.

Unpacked:

• CELMoDs represent a novel mechanism that modulates protein degradation pathways, offering a differentiated approach to treating blood cancers.
• The approval stems from the original Celgene acquisition and demonstrates BMS is extracting value from that massive investment.
• This first-in-class designation positions BMS ahead of competitors developing similar mechanisms for hematologic malignancies.

Amylyx Pivotal Trial Success with GLP-1 Blocker Avexitide

Amylyx Pharmaceuticals reported positive pivotal trial results for avexitide, a GLP-1 receptor blocker designed to treat severe hypoglycemia in patients following bariatric surgery. The success represents a strategic pivot for the company after previous setbacks.

Unpacked:

• Avexitide blocks GLP-1 receptors, the opposite mechanism of popular weight loss drugs, addressing dangerous blood sugar drops post-surgery.
• The Phase 3 success positions Amylyx for regulatory filing in an underserved patient population with limited treatment options.
• This marks a turnaround for Amylyx, which faced challenges with its previous ALS drug and needed a commercial win.

Argenx Expands Vyvgart Franchise with Phase 3 Autoimmune Wins

Argenx announced positive Phase 3 data for Vyvgart in immune-mediated necrotizing myopathy and dermatomyositis, two rare autoimmune conditions. The company plans to file for FDA approval, potentially adding blockbuster indications to its already successful drug.

Unpacked:

• Vyvgart already generates significant revenue in other autoimmune diseases, and these new indications could substantially expand market opportunity.
• Analysts view IMNM and dermatomyositis as potentially lucrative additions given limited existing treatment options for these conditions.
• Company shares jumped on the announcement, reflecting investor confidence in Vyvgart's expanding commercial potential across multiple indications.

IRS Investigates UnitedHealth Group Over Tax Practices

The Internal Revenue Service has opened an investigation into UnitedHealth Group examining potential tax avoidance related to foreign subsidiary transfers. The probe adds to mounting regulatory pressure on the nation's largest health insurer.

Unpacked:

• The investigation focuses on how UnitedHealth structured transfers involving foreign subsidiaries, raising questions about tax compliance strategies.
• This scrutiny comes amid broader concerns about UnitedHealth's business practices and market dominance in healthcare insurance and services.
• The probe coincides with reports of slowing private equity deals in physician practice management, suggesting increased regulatory attention industrywide.

The Shortlist

• AstraZeneca discontinued a Phase 3 trial of its bispecific antibody volrustomig in lung cancer after disappointing results.

• Sanofi will lay off 229 workers in Massachusetts and close Cambridge offices following its $9.1 billion Blueprint Medicines acquisition.

• EyePoint Pharmaceuticals saw shares plummet after its lead drug Duravyu missed endpoints in a pivotal trial for wet age-related macular degeneration.

• Sandoz struck a $322 million deal with Shanghai Henlius to expand its biosimilars portfolio in key markets.